-
1021
-
1022
Gas Plasma Exposure of Glioblastoma Is Cytotoxic and Immunomodulatory in Patient-Derived GBM Tissue
Published 2022-02-01“…In summary, the immuno-modulatory and proapoptotic action shown in this study might be an important step forward to first clinical observational studies on the future discovery of gas plasma technology’s potential in neurosurgery and neuro-oncology especially in putative adjuvant or combinatory GBM treatment settings.…”
Get full text
Article -
1023
-
1024
-
1025
Bevacizumab in recurrent WHO grades II–III glioma
Published 2023-07-01“…Efficacy was assessed using the high-grade glioma 2017 Response Assessment in Neuro-Oncology criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method.ResultsEighty-one patients were included (M/F ratio: 1.7, median age at diagnosis: 38 years) among whom 46 (56.8%) had an initial diagnosis of grade II glioma. …”
Get full text
Article -
1026
Time to surgery after radiological diagnosis of brain tumours in Pakistan: A nationwide cross-sectional study
Published 2022-12-01“…Keywords: Treatment delay, Neuro-oncology, Time to surgery, Neurosurgery. …”
Get full text
Article -
1027
Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score
Published 2021-04-01Get full text
Article -
1028
-
1029
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Published 2022-03-01Get full text
Article -
1030
A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value
Published 2021-05-01“…Background: Pediatric high-grade gliomas (pHGGs) are the leading cause of mortality in pediatric neuro-oncology, displaying frequent resistance to standard therapies. …”
Get full text
Article -
1031
-
1032
-
1033
Systemic and local immunosuppression in glioblastoma and its prognostic significance
Published 2024-02-01“…We call for the inclusion of dynamic assessment of NLR and other blood inflammatory markers (e.g., absolute/total lymphocyte count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, and systemic immune response index) in all neuro-oncology studies for rigorous evaluation and comparison of their individual and combinatorial prognostic/predictive significance and relative superiority.…”
Get full text
Article -
1034
-
1035
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
Published 2021-12-01Get full text
Article -
1036
-
1037
Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study
Published 2023-04-01“…A consecutive cohort of unselected patients (real-world data) from three neuro-oncology cancer centers was analyzed (a total of 109 patients). …”
Get full text
Article -
1038
-
1039
Incidence of malignant brain and other central nervous system tumors (С70–C72) in Siberia and the Russian Far East
Published 2022-02-01“…The development and implementation of a Neuro-Oncology Registry in accordance with the international standards will allow full analysis of the epidemiological situation of malignant brain and other central nervous system tumors.…”
Get full text
Article -
1040
Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma
Published 2023-11-01Get full text
Article